
Opinion|Videos|July 29, 2024
Biosimilars in the Commercial Sector
Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are payers and PBMs making decisions about biosimilars in the commercial sector?
a. What key factors are considered for formulary decisions in the commercial sector?
b. Discussion points: What makes the commercial sector unique, employer/payer payment models.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
3
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
4
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
5